Simcyp-led Linked-in Live Event Draws Hundreds of Registrants
Simcyp led a panel discussion on the benefits of using physiologically-based pharmacokinetic modeling & simulation for 2 vulnerable populations—pregnancy and pediatrics.
Simcyp led a panel discussion on the benefits of using physiologically-based pharmacokinetic modeling & simulation for 2 vulnerable populations—pregnancy and pediatrics.
2022年11月3日ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), a global leader in biosimulation, today announced that eight of the Company’s scientists have been featured in a list of the top 2% of scientists worldwide. The list was published in mid-October 2022 by Elsevier BV and Stanford University. The ranking of scientists worldwide is based on a composite … Continued
ISoP recognizes innovative science and outstanding leadership in the field of Pharmacometrics and related scientific areas PRINCETON, NJ.— 2022年11月2日 – Certara, Inc., the global leader in biosimulation, today announced that Amin Rostami, Ph.D and Geoff Tucker, Ph.D., co-founders of Simcyp (now, a division of Certara), have received the 2022 Innovation Award by the … Continued
PRINCETON, N.J.— 2022年10月12日 – Certara, Inc., a global leader in drug development software, today announced the release of the PK Submit™ 2.0. The software allows scientists to automatically create a complete electronic pharmacokinetic (PK) regulatory submission-ready data package within minutes during the normal process of setting up and executing a non-compartmental analysis (NCA). … Continued
Certara Shanghai relocated the office and held a grand opening ceremony at Hong Kong Plaza in Huangpu District, Shanghai on 2022年9月9日. The goal of this move was to provide greater support to local customers and facilitate meeting market needs. Customers and key opinion leaders in China were invited to the ceremony where they … Continued
PRINCETON, N.J., 2022年9月25日 – Certara, a global leader in biosimulation, today announced it will host the second annual New Horizons in Pediatric Drug Development Symposium from October 27-28, 2022. The two-day virtual symposium brings together global thought leaders from academia, industry, patient advocacy organizations and health authorities to discuss the latest innovations in … Continued
PRINCETON, N.J.— 2022年9月25日 — Certara, Inc, a global leader in biosimulation, today announced that it is expanding its Applied Pharmacometrics Training (APT) fellowship program for doctoral-level scientists from Africa, in partnership with Pharmacometrics Africa, CP+ Associates, and other industry and academic partners. After its successful first year with sixteen fellows, the program has … Continued
The Rare Disease Research Consortim (IRDiRC) recognizes that rare disease therapeutics and orphan drug development represent unique scientific challenges. We are thrilled to share that Certara’s Senior Director of Regulatory Strategy, Oxana Iliach, PhD. has been elected a member of the newly created Regulatory Science Committee at IRDiRC to help tackle regulatory challenges in rare … Continued
Software that predicts risk of novel drug safety recognized in Software/Services category PRINCETON, NJ – 2022年8月25日 – Certara, Inc., a global leader in biosimulation, today announced that its Secondary Intelligence software has won an R&D 100 Award, which recognizes the top 100 “R&D pioneers and their revolutionary ideas in science and technology” each … Continued
Princeton, NJ, 2022年5月17日. Certara, Inc., a global leader in biosimulation, today announced that the Company was Certified™ by Great Place to Work® in its first year of participation. The prestigious award is based entirely on what current employees say about their experience working at Certara. This year, 88% of employees said it’s a … Continued